ATTENTION: The software behind KU ScholarWorks is being upgraded to a new version. Starting July 15th, users will not be able to log in to the system, add items, nor make any changes until the new version is in place at the end of July. Searching for articles and opening files will continue to work while the system is being updated.
If you have any questions, please contact Marianne Reed at mreed@ku.edu .
Creatine as a Therapeutic Target in Alzheimer's Disease
dc.contributor.author | Smith, Aaron N. | |
dc.contributor.author | Morris, Jill K. | |
dc.contributor.author | Carbuhn, Aaron F. | |
dc.contributor.author | Herda, Trent J. | |
dc.contributor.author | Keller, Jessica E. | |
dc.contributor.author | Sullivan, Debra K. | |
dc.contributor.author | Taylor, Matthew K. | |
dc.date.accessioned | 2024-06-03T18:42:26Z | |
dc.date.available | 2024-06-03T18:42:26Z | |
dc.date.issued | 2023-09-29 | |
dc.identifier.citation | Smith AN, Morris JK, Carbuhn AF, Herda TJ, Keller JE, Sullivan DK, Taylor MK. Creatine as a Therapeutic Target in Alzheimer's Disease. Curr Dev Nutr. 2023 Sep 29;7(11):102011. doi: 10.1016/j.cdnut.2023.102011. PMID: 37881206; PMCID: PMC10594571 | en_US |
dc.identifier.uri | https://hdl.handle.net/1808/35092 | |
dc.description.abstract | Alzheimer's disease (AD) is the most prevalent neurodegenerative disease, affecting approximately 6.5 million older adults in the United States. Development of AD treatment has primarily centered on developing pharmaceuticals that target amyloid-β (Aβ) plaques in the brain, a hallmark pathological biomarker that precedes symptomatic AD. Though recent clinical trials of novel drugs that target Aβ have demonstrated promising preliminary data, these pharmaceuticals have a poor history of developing into AD treatments, leading to hypotheses that other therapeutic targets may be more suitable for AD prevention and treatment. Impaired brain energy metabolism is another pathological hallmark that precedes the onset of AD that may provide a target for intervention. The brain creatine (Cr) system plays a crucial role in maintaining bioenergetic flux and is disrupted in AD. Recent studies using AD mouse models have shown that supplementing with Cr improves brain bioenergetics, as well as AD biomarkers and cognition. Despite these promising findings, no human trials have investigated the potential benefits of Cr supplementation in AD. This narrative review discusses the link between Cr and AD and the potential for Cr supplementation as a treatment for AD. | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Copyright © 2023 The Authors This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). | en_US |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | en_US |
dc.subject | Alzheimer’s disease | en_US |
dc.subject | Creatine | en_US |
dc.subject | Brain | en_US |
dc.subject | Bioenergetics | en_US |
dc.subject | Mitochondria | en_US |
dc.title | Creatine as a Therapeutic Target in Alzheimer's Disease | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Herda, Trent J. | |
kusw.kudepartment | Department of Health, Sport and Exercise Sciences | en_US |
dc.identifier.doi | 10.1016/j.cdnut.2023.102011 | en_US |
kusw.oaversion | Scholarly/refereed, publisher version | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC10594571 | en_US |
dc.rights.accessrights | openAccess | en_US |